Beyond Air (NASDAQ:XAIR) Announces Quarterly Earnings Results

Beyond Air (NASDAQ:XAIR) released its earnings results on Thursday. The company reported ($11.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($10.80) by ($0.20), Zacks reports. Beyond Air had a negative net margin of 432.99% and a negative return on equity of 350.00%.

Here are the key takeaways from Beyond Air’s conference call:

• Second-quarter revenue was $1.8 million, essentially flat year over year and sequentially. Gross margin improved to 13%, marking the third consecutive quarter of positive gross profit, although the company still reported a $7.9 million net loss.
• Beyond Air raised $10 million upfront through financing with potential for up to an additional $20 million from warrant exercises, strengthening its ability to fund Gen 2 LungFit PH production, commercial preparations, and international expansion.
• The company said its Gen 2 LungFit PH submission remains on track for potential FDA approval in the second half of 2026, with audits and pilot builds underway. Management described FDA communication as strong but cautioned that timing remains subject to the agency’s review.
• Commercial momentum is building, including a new national group purchasing agreement that gives Beyond Air access to a substantial portion of U.S. hospitals, a pipeline that management says has doubled over the past five to six months, and distribution partnerships spanning more than 40 countries.
• Management reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million; the 2027 outlook includes potential Gen 2 LungFit PH revenue, while the 2026 forecast excludes any contribution from the new system.

Beyond Air Stock Performance

Shares of XAIR traded up $0.35 during midday trading on Thursday, reaching $6.41. 30,201 shares of the stock were exchanged, compared to its average volume of 163,520. The business’s 50-day moving average price is $7.19 and its 200 day moving average price is $12.44. The company has a debt-to-equity ratio of 3.48, a current ratio of 3.80 and a quick ratio of 3.59. Beyond Air has a twelve month low of $5.02 and a twelve month high of $95.60. The company has a market capitalization of $4.61 million, a price-to-earnings ratio of -0.07 and a beta of 0.23.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Beyond Air in a report on Tuesday, July 21st. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $200.00.

Insider Activity

In other news, CEO Robert Scott Goodman purchased 34,722 shares of the business’s stock in a transaction on Wednesday, July 29th. The shares were bought at an average price of $5.76 per share, with a total value of $199,998.72. Following the completion of the transaction, the chief executive officer directly owned 34,822 shares in the company, valued at approximately $200,574.72. This represents a 34,722.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.99% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Beyond Air

Hedge funds have recently modified their holdings of the business. Geode Capital Management LLC raised its position in Beyond Air by 57.5% in the 4th quarter. Geode Capital Management LLC now owns 67,678 shares of the company’s stock valued at $49,000 after purchasing an additional 24,695 shares during the last quarter. Alyeska Investment Group L.P. purchased a new position in Beyond Air during the 3rd quarter worth $1,753,000. Virtu Financial LLC acquired a new position in Beyond Air in the third quarter valued at $48,000. Finally, Osaic Holdings Inc. increased its stake in Beyond Air by 26.4% in the second quarter. Osaic Holdings Inc. now owns 162,560 shares of the company’s stock valued at $29,000 after purchasing an additional 34,000 shares during the period. 31.50% of the stock is currently owned by hedge funds and other institutional investors.

Beyond Air Company Profile

Beyond Air, Inc is a clinical-stage medical technology company focused on the development and commercialization of inhaled nitric oxide (NO) therapy for pulmonary and respiratory diseases. The company’s proprietary LungFit® platform delivers pulsed, low-dose nitric oxide gas through compact, portable devices designed to support treatments in both inpatient and outpatient settings. Beyond Air’s approach leverages NO’s antimicrobial, vasodilatory and anti-inflammatory properties to address a range of unmet needs in respiratory medicine.

The company’s lead candidate, LungFit® PH, is under investigation for the treatment of pulmonary hypertension, with ongoing clinical studies assessing its impact on pulmonary arterial pressure and exercise capacity.